Smad2 and Smad3 (mothers against decapentaplegic homolog 2 and 3) (Smad2/3)

Smad2 and Smad3 are intracellular transcription factors of the Smad family that become phosphorylated in response to activation of TGF-β and activin receptors, specifically when type I receptor kinases phosphorylate the C-terminal SXS motif. Upon phosphorylation, Smad2 and Smad3 form complexes with Smad4 and translocate to the nucleus, where they regulate the transcription of target genes involved in processes such as cell proliferation, differentiation, and migration. The phosphorylation status is highly regulated by various kinases (TGF-βRI/ALK5, MAPKs, CDKs, etc.) and counterbalanced by phosphatases and degradation, modulating the amplitude and duration of TGF-β signaling. Altered Smad2/3 activity is implicated in multiple disease processes, notably cancers and fibrotic diseases, making the pathway a targetable axis for therapeutic intervention.

Other names

Smad2Smad3R-Smad2R-Smad3mothers against decapentaplegic homolog 2/3receptor-regulated Smad2/3

Inhibition of TGF-β type I receptor kinase prevents Smad2/3 phosphorylation and activation (e.g., with small molecules like SB-431542). Direct targeting of Smad proteins is rare; mostly, interventions target upstream or modifying kinases.